Longeveron Inc. received Fast Track designation from the FDA on August 20, 2025, and subsequently announced its activities regarding the MSC therapy product.
4 reports, 1 independent
Updated Aug 20
Gone quiet
- Reports
- 4
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Longeveron Inc. received Fast Track designation from the FDA on August 20, 2025, and subsequently announced its activities regarding the MSC therapy product.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Longeveron Inc. gains Fast Track designation from FDA; announces social media presence and conference presentation in NYC.1 source
Longeveron Inc. announced its offering in Miami.1 source
Keep exploring
The entities involved
Related events
- FDA granted Fast Track designation to NRX-100 on September 4, 2025.
- Iovance Biotherapeutics listed its stock on Nasdaq and received Fast Track designation from the FDA.
- Decoy Therapeutics is listed on the Nasdaq stock exchange and is currently seeking expedited regulatory approval via FDA pathways.
- Iovance Biotherapeutics received FDA approval for its therapy, and the company is listed on Nasdaq.
- Mylan is seeking regulatory approval from the FDA for new products and has listed its stock on the Nasdaq exchange.
Coverage
Newest first; wire copies grouped- GlobeNewswireLongeveron® to Present at the H.C. Wainwright 27th Annual Global Investment Conference MIAMI, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine
- GlobeNewswireLongeveron Announces Closing Of Up To $17.5 Million Public Offering $5.0 million upfront with up to an additional $12.5 million of potential aggregate gross proceeds upon the exercise in full of shor
- GlobeNewswireLongeveron® to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025 MIAMI, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regen
- Unknown outlet